Asset
Zelebrudomide
Nurix Therapeutics Inc. Common stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04830137 | phase1 | recruiting | 2021-05-05 | 2026-05-01 | Nurix Therapeutics, Inc. | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies |
FDA applications (0)
This company has no applications containing this asset.